refractory myasthenia gravis
Chronic Disease Management Isn't About MG - BTK Is
Ibrutinib, a BTK inhibitor, delivers rapid strength gains for refractory myasthenia gravis, with 52% of patients reporting over 30% improvement within three months. This targeted approach challenges the traditional reliance on broad immunosuppression, offering a more precise route for chronic disease management. Medical Disclaimer: This article is for informational purposes